WALTHAM, MA--(Marketwire - April 14, 2008) - EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye for treating serious ocular diseases, today announced the initiation of a Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System in up to 95 healthy adult volunteers. This is a single center, randomized, single masked, comparative-group safety and tolerability study of a range of single iontophoretic dose levels with a citrate buffer via the EyeGate® II Delivery System.
